FocalTherics (EDA) Price & Analysis
EDA Stock Chart & Stats
- Day’s Range
- EUR 3.60 - EUR 3.70
- 52-Week Range
- EUR 1.65 - EUR 5.35
- Previous Close
- EUR 3.70
- Volume
- 220
- Average Volume (3M)
- 0
- Market Cap
- EUR 139.82M
- Enterprise Value
- EUR 214.53M
- Total Cash (Recent Filing)
- EUR 21.54M
- Total Debt (Recent Filing)
- EUR 39.89M
- Price to Earnings (P/E)
- ―
- Beta
- 0.92
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- -0.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
HIFU Growth And Installed Base
Strong system sales and a larger installed base expand market reach and create a foundation for recurring consumables, service revenue and procedure growth over the next several quarters.
Procedure Utilization And Margin Expansion
Higher utilization supports recurring revenue from consumables and services, while improved gross margin indicates potential operating leverage from lower system costs, pricing and scale.
Reimbursement And Indication Expansion
Improving reimbursement can strengthen hospital economics, while additional indications broaden the addressable market and diversify long-term growth beyond prostate cancer treatment.
Bears Say
Persistent Losses And Revenue Contraction
Sustained operating and net losses despite relatively stable revenue indicate that commercialization costs remain too high, limiting internal funding capacity and delaying a durable path to profitability.
Weak Balance Sheet And Funding Dependence
Negative equity, rising debt and continued cash burn reduce financial flexibility. The completed equity raise improves liquidity, but ongoing reliance on external capital remains a structural risk.
High Costs And Early-Stage Diversification
Elevated spending can prolong losses before new indications contribute meaningfully. Execution, regulatory and adoption risks therefore remain significant while the company funds commercial expansion and R&D.
FocalTherics News
EDA FAQ
What was FocalTherics’s price range in the past 12 months?
What is FocalTherics’s market cap?
When is FocalTherics’s upcoming earnings report date?
How were FocalTherics’s earnings last quarter?
Is FocalTherics overvalued?
Does FocalTherics pay dividends?
What is FocalTherics’s EPS estimate?
How many shares outstanding does FocalTherics have?
What happened to FocalTherics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of FocalTherics?
What is the TipRanks Smart Score and how is it calculated?
FocalTherics Stock Smart Score
Company Description
FocalTherics
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ryan Rhodes
- Employees
- 289
- Website
- www.focalone.com
- Address
- Parc d’Activites la Poudrette-Lamartine, Vaulx-en-Velin, ARA, 69120, FR
FocalTherics (EDA) Earnings & Revenues
EDA Earnings Call
Earnings Call SentimentPositive
The call conveyed clear commercial momentum: double-digit revenue growth (39% YoY), record capital system sales, strong procedure volume growth (47% YoY), margin improvement to 55.6%, meaningful regulatory/reimbursement progress, and a near-term $40M equity raise to fund commercial expansion and R&D. Offsetting these positives are rising operating expenses, a sizable noncash warrant charge ($6.3M) that pushed shareholder equity negative ($-3.2M), reliance on the pending equity raise to strengthen the balance sheet, and a 34% decline in discontinued operations revenue. On balance, the business shows accelerating revenue, improving margins and strategic progress that outweigh the financial and accounting headwinds, with the upcoming equity close expected to materially improve capitalization.
View all DE:EDA earnings summariesEDA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 4 | 7 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 8 | 0 | 4 |